Managing recurrent central nervous system malignancies represents a persistent clinical dilemma. Patients with relapsed CNS lymphoma typically experience poor prognoses and limited therapeutic options after initial high-dose methotrexate failure. However, molecularly targeted strategies offer fresh opportunities to overcome chemoresistance. Recently, investigators evaluated an oral-intravenous combination known as R2I, uniting the Bruton's tyrosine kinase inhibitor ibrutinib, the immunomodulatory drug lenalidomide, and the anti-CD20 monoclonal antibody rituximab. This prospective investigation assessed safety, tolerability, and tumor responses in heavily pretreated individuals.

The Therapeutic Challenge of Relapsed CNS Lymphoma

Primary and secondary central nervous system lymphomas carry aggressive biological features. While front-line high-dose methotrexate-based regimens induce remissions, a substantial fraction of patients experience early relapse. Furthermore, salvage whole-brain radiotherapy carries substantial neurotoxicity risks, particularly in older patients. Second-line cytotoxic chemotherapies often fail to cross the blood-brain barrier effectively. Consequently, durable disease control remains elusive in daily neuro-oncology practice.

Therefore, clinicians urgently need brain-penetrant regimens that maintain systemic potency without compounding neurocognitive decline. Small molecules that penetrate the central nervous system offer considerable pharmacological advantages over classical polar antineoplastic agents. Preclinical studies demonstrated that combining targeted pathway inhibition with immunomodulation disrupts critical B-cell survival pathways. As a result, researchers designed the R2I protocol to exploit synergistic antitumor mechanisms while minimizing organ toxicity.

Mechanistic Rationale Behind the Triplet Regimen

Diffuse large B-cell lymphomas arising in the brain rely heavily on chronic active B-cell receptor signaling. Specifically, mutations activating the MYD88 and CD79B pathways frequently drive malignant cellular proliferation. Ibrutinib selectively inhibits Bruton's tyrosine kinase, thereby shutting down downstream survival cascades. Moreover, ibrutinib achieves meaningful therapeutic concentrations within the cerebrospinal fluid and brain parenchyma.

However, monotherapy often fosters rapid secondary resistance. To overcome this limitation, researchers added lenalidomide to the treatment backbone. Lenalidomide alters cereblon E3 ubiquitin ligase activity, which degrades transcription factors essential for lymphoma survival. In addition, lenalidomide enhances natural killer cell function and antibody-dependent cellular cytotoxicity. Rituximab complements these cellular effects by targeting surface CD20 antigens. Together, these three agents exert multi-targeted pressure on refractory neoplastic clones.

Trial Design and Dose Escalation Protocol

Investigators conducted a multicenter phase Ib trial with a subsequent dose expansion cohort. The study evaluated escalating doses of ibrutinib and lenalidomide alongside standard rituximab. Specifically, ibrutinib was administered continuously at either 560 mg daily for dose level 1 or 840 mg daily for levels 2 through 4. Meanwhile, lenalidomide was administered on days 1 through 21 of each 28-day cycle at doses of 10 mg, 15 mg, or 20 mg daily.

Rituximab was administered at 500 mg/m2 once every 28 days for a planned total of 6 cycles. Lenalidomide therapy continued for up to 12 cycles, whereas patients continued daily ibrutinib until disease progression or intolerable toxicity. The trial enrolled 25 patients across all cohorts. The study cohort presented a median age of 67 years, ranging between 41 and 85 years. Furthermore, enrolled individuals had received a median of 2 prior systemic regimens, illustrating substantial therapeutic pre-exposure.

Clinical Efficacy and Survival Outcomes

The combination demonstrated remarkable antineoplastic activity in this challenging population. Overall, 20 out of 25 enrolled patients achieved an objective tumor response, yielding an impressive 80% response rate. Additionally, responses occurred rapidly after treatment initiation. The median time to best radiographic response was merely 60 days, providing swift symptomatic relief to patients suffering from intracranial mass effects.

Nevertheless, long-term disease stabilization varied across the cohort. After a median follow-up of 12.8 months, the median progression-free survival reached 4.3 months. Importantly, 37% of patients remained free of disease progression at 12 months, demonstrating prolonged disease control in a clinically meaningful subset. At the time of reporting, median overall survival had not been reached. These findings indicate that the R2I regimen provides rapid debulking and durable remission for select patients with relapsed disease.

Safety Profile and the Rash Biomarker Correlation

Overall, patients tolerated the R2I combination satisfactorily without unexpected toxicities. The most frequent adverse events included thrombocytopenia, maculopapular rash, and lymphopenia. Hematologic toxicities remained manageable with standard supportive care and dose adjustments. Crucially, clinicians observed no cases of invasive aspergillosis, an infectious complication previously linked to Bruton's tyrosine kinase inhibitor therapy. Moreover, no grade 5 treatment-related deaths occurred during the trial.

Interestingly, the development of a cutaneous rash correlated strongly with superior progression-free survival. Patients who developed a treatment-emergent rash exhibited a hazard ratio for progression of 0.17 compared to those who did not. This statistically significant association suggests that cutaneous toxicity may serve as a clinical surrogate marker for heightened immune activation or robust drug bioavailability. Consequently, clinicians should manage dermatologic symptoms proactively rather than discontinuing treatment prematurely.

Clinical Implications for Oncology Practice

These findings carry meaningful relevance for oncologists managing refractory neuro-oncology cases. First, the regimen is primarily oral, reducing frequent hospital visits for elderly or frail patients. Second, the rapid onset of tumor regression makes R2I an attractive salvage bridge to autologous stem cell transplantation or cellular therapies. Therefore, multidisciplinary teams can consider this triplet when conventional chemotherapy fails.

Additionally, the trial establishes the recommended phase 2 dosing scheme, identifying ibrutinib 840 mg daily and lenalidomide 20 mg daily as safe. Clinicians should ensure rigorous monitoring of complete blood counts during early cycles. Prophylactic anti-infective measures and prompt management of hematologic toxicities ensure uninterrupted therapy. Ultimately, larger comparative trials will help define optimal sequencing strategies for this targeted approach.

Frequently Asked Questions

What was the overall response rate seen with R2I?

In this phase Ib trial, the R2I combination produced an overall response rate of 80% among 25 enrolled patients. Furthermore, tumor regression occurred rapidly, with a median time to best response of 60 days. This rapid activity offers critical clinical benefit for patients facing acute intracranial tumor progression.

Which adverse events were most common during the trial?

The most commonly reported adverse events included thrombocytopenia, maculopapular skin rash, and lymphopenia. Most toxicities remained clinically manageable with dose modifications and supportive interventions. Importantly, investigators noted no instances of invasive aspergillosis, and no grade 5 treatment-related toxicities occurred during the study follow-up period.

How did treatment-induced rash correlate with clinical outcomes?

Patients who experienced treatment-emergent rash demonstrated significantly improved progression-free survival compared to patients without cutaneous symptoms. The calculated hazard ratio for progression was 0.17, indicating substantial risk reduction. Thus, dermatologic reactions may reflect robust immune engagement and therapeutic drug exposure rather than simple adverse toxicity.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Schaff LR et al. Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma. Neuro Oncol. 2025 Sep 17. doi: 10.1093/neuonc/noaf104. PMID: 40269592.
2. Soussain C, Choquet S, Blonski M, et al. Ibrutinib monotherapy for patients with primary or secondary central nervous system lymphoma: a study of the French LOC network. Neuro Oncol. 2019;21(8):1069-1076.
3. Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018-1029.